Clinical trials: Osteoporosis Postmenopausal
Back Pain
The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
The primary objective of this trial is to show that PTH(1-84) is superior to alendronate in reducing back pain intensity over a 24-week treatment period in postmenopausal women with an osteoporosis related vertebral fracture(s).
- Trial name
- NCT00713258
- Testing
- Parathyroid hormone (PTH) (1-84), Alendronate
- Where
- Denmark
- Volunteers
- 75 people
- Sponsor
- Nycomed
Osteoporosis, Postmenopausal
Effect of Mechanical Loading With PTH on Cortical Bone
Clinical trial to investigate effect of voluntary upper extremity loading in combination with anabolic osteoporosis therapy.
- Trial name
- NCT03232476
- Testing
- Upper extremity voluntary loading
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Osteopenia
Periodontal Disease and Post-menopausal Osteoporosis
The aim of this study was to investigate the levels of RANKL and Osteoprotegerin, and their relationship in gingival crevicular fluid of post-menopausal women with osteoporosis/osteopenia and chronic periodontitis simultaneously…
- Conditions
- Osteoporosis, Osteopenia, Periodontal Disease
- Trial name
- NCT02184962
- Where
- Argentina
- Volunteers
- 81 people
- Sponsor
- Universidad Nacional de Córdoba
Breast Cancer, Osteoporosis
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more…
- Trial name
- NCT00688246
- Testing
- biologic sample preservation procedure, dual x-ray absorptometry
- Where
- 18 sites in United States, Canada
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- NCIC Clinical Trials Group
Osteoporosis
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
- Trial name
- ROSE (NCT00404820)
- Testing
- Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Novartis
Osteoporosis, Postmenopausal, Physical Activity
Efficacy and Safety of the Physical Activity Program in Women With Post-menopausal Osteoporosis
The study will be single blinded since professionals who will evaluate patients will not know to which exercise group patients have been assigned.
- Trial name
- ACTLIFE (NCT04179903)
- Testing
- Physical activity
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Istituto Ortopedico Rizzoli
Post-menopausal Osteoporosis
Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
A study to determine if the three licensed bisphosphonates (alendronate, ibandronate and risedronate):a) affect the peripheral skeleton differently, as assessed by quantitative ultrasound of bone (QUS), peripheral quantitative…
- Trial name
- NCT00666627
- Testing
- Ibandronate, Risedronate, Alendronate
- Where
- United Kingdom
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Osteoporosis, Fall Patients
Relationships Among Body Mass Index, Body Balance and Bone Mineral Density in Postmenopausal Women
Body composition, bone mineral density (BMD), and body balance are important factors that threaten postural control. They act as vital elements in the vicious circle that leads to fracture occurrence in elderly population…
- Conditions
- Osteoporosis, Fall Patients, Postmenopausal Disorder
- Trial name
- NCT03280693
- Testing
- Diagnostic test
- Volunteers
- 48 people
- Sponsor
- Cairo University
Postmenopausal Osteoporosis
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed…
- Trial name
- NCT00577421
- Testing
- risedronate
- Where
- 5 sites in Australia, Italy and 3 more
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Osteoporosis
Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice
The vitamin D deficiency (25OHD) is very common and affects about 80% of the population of French osteoporotic women over 50 years [5]. It contributes significantly to bone fragility and consequently the risk of fracture.
- Trial name
- VITAD (NCT02518763)
- Testing
- Vitamin D3, 100 000 IU weekly, 4 times, 25 OH vitamin D serum concentration measurements
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Osteoporosis
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
This is a double-blinded randomized study to determine the effects of treatment on biochemical markers of bone formation and bone resorption, and bone mineral density (BMD) for 6 months of treatment with EBP05 or placebo.
- Trial name
- NCT04003467
- Testing
- EBP05
- Where
- 4 sites in Israel
- Volunteers
- 161 people
- Sponsor
- Entera Bio Ltd.
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Differentiated Thyroid Cancer, Osteoporosis
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis.
- Trial name
- NCT02304757
- Testing
- 99Tc-MDP, Fosamax
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Osteoporosis, Post-Menopausal
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis
- Trial name
- NCT00532207
- Testing
- teriparatide
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
Clodronic acid 100 mg/3,3 ml is used to prevent and treat postmenopausal osteoporosis. The intramuscular formulation, which is given at a dose of 100 mg every 7 o 14 days, is at least as effective as daily oral therapy and…
- Trial name
- NCT01348243
- Testing
- disodium clodronate 200 mg/4 ml with 1% lidocaine, Disodium clodronate 100 mg/3,3 ml with 1% lidocaine
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Breast Cancer, Osteoporosis
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.
- Trial name
- NCT00369850
- Testing
- laboratory biomarker analysis, Dual energy X-ray absorptiometry (DEXA), Spine X-ray
- Where
- 16 sites in Australia, France and 6 more
- Volunteers
- 458 people
- Sponsor
- ETOP IBCSG Partners Foundation
Osteoporosis, Postmenopausal
Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)
Efficacy: To investigate changes of structural bone properties in vivo using 3DpQCT ("Xtreme" CT, Scanco) in monthly oral ibandronate therapy for women with postmenopausal osteoporosis.
- Trial name
- NCT00271713
- Testing
- ibandronate, calcium and vitamin D
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Charite University, Berlin, Germany
Postmenopausal Osteoporosis, Postmenopause
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world.
- Conditions
- Postmenopausal Osteoporosis, Postmenopause, Hyperparathyroidism, Secondary, Hypovitaminosis D
- Trial name
- NCT05347082
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 47 people
- Sponsor
- Hospital Regional 1o de Octubre
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline